Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Debating the value of targeted lung cancer treatments

US industry group Pharmaceutical Research and Manufacturers of America (PhRMA) has criticised an evidence report by the Institute for Clinical and Economic Review (ICER), which puts a low value on targeted treatments and immunotherapy for non-small cell lung cancer. ICER’s findings fly in the face of the trend towards individualised cancer treatment, but Abi Millar asks who is right in this case.

Go Top